Drug profile · INN
moxetumomab pasudotox-tdfk
LUMOXITI
moxetumomab pasudotox-tdfk (LUMOXITI) is a cd22 binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — moxetumomab pasudotox-tdfk
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
moxetumomab pasudotox-tdfk (LUMOXITI) is a cd22 binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
CD22 binding agent
Primary target: B-cell receptor CD22
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is moxetumomab pasudotox-tdfk?
moxetumomab pasudotox-tdfk (LUMOXITI) is a cd22 binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for moxetumomab pasudotox-tdfk?
LUMOXITI is a marketed brand name for moxetumomab pasudotox-tdfk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of moxetumomab pasudotox-tdfk?
moxetumomab pasudotox-tdfk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.